Member Info for Downagain

No it won't 😂

Flying up now 😀

Moving up on any volume

Could test .6 again today 😀😀🚀🚀

The market is never wrong

Warrants for the boys 5 years and massive dilution what's not to like, and bugger all gold in the actual one closer to production. The option is the better bet

Look at NTVO, imminent gold mining at under 3m mc

Says 8 trades but only 2 showing??

Think another biggish trade to show up soon then onwards and upwards

More buys than sells again and no movement??

Think we will get some sample updates soon maybe even tomorrow. Think we may be in for a lovely surprise on grades , bonanza gor a reason 😄😄🚀🚀🚀

Think we will get some sample updates soon maybe even tomorrow. Think we may be in for a lovely surprise on grades , bonanza gor a reason 😄😄🚀🚀🚀

Can't see that tbh, too much news. 2.5m buys unanswered since 1230 😁

I don't think the research note it right, the dates are nonsense tbh it's really poor.

Quiet today

Think they just need to update clearly and transparently

Nice consolidation now for next leg up 🚀🚀🚀

Post please?

Oops

Group Restructuring

The Company intends to carve out the value of the Lyramid SPA and the MK Cell Out-License for the benefit of existing shareholders and convertible loan holders. In order to facilitate this, the Company has recently undertaken the following restructuring of the Group (the "Group Restructuring"):

a) The entire issued shares of Lyramid have been acquired by Midkine Investments (a 100% owned subsidiary of Roquefort Therapeutics) such that Lyramid is now 100% owned by Midkine Investments; and

b) The rights to the MK Cell program held by Oncogeni Ltd have been novated to Midkine Investments such that Midkine Investments now holds the underlying exclusive worldwide rights to the MK Cell program.

It is the intention of the Company to issue new unlisted redeemable non-voting shares ("Unlisted RNV Shares") to the holders of Roquefort Therapeutics ordinary shares and convertible loan notes listed on the Company's registers as at 30 November 2025. The Unlisted RNV Shares will entitle holders to all commercial benefits from Midkine Investments with the ultimate aim of undertaking an in-specie distribution of the Midkine Investments shares once the balance sheet of the Company permits such an action under the Companies Act.

London South East

Check out our new Alternative Investment section.Click here

Share PricesRoquefort Thera Share PriceRoquefort Thera Share Regulatory NewsMK Cell Out-License & Lyramid SPA Update

Pin to quick picksRoquefort Thera Regulatory News (ROQ)

ROQ Share Price

ROQ Share

Price

ROQ Share News

ROQ Share

News

ROQ Share Chat

ROQ Share

Chat

10

ROQ Share Trades

ROQ Share

Trades

ROQ Live RNS

ROQ

Live RNS

Sponsored Content

Roquefort Thera Information

Add ROQ to Timeline

Add ROQ to Timeline

Add ROQ to Watchlist

Add ROQ to Watchlist

Add ROQ to Alert

Add ROQ to Alert

Buy ROQ Shares

Buy ROQ Shares

Share Price Information for Roquefort Thera (ROQ)

Share Price is delayed by 15 minutes

Get Live Data

1.30

0.00 (0.00%)

Bid:

1.20

Ask:

1.40

Spread: 0.20 (16.667%)Market Cap: £2.13m

ROQ Live PriceLast checked at 10:53:52London Stock Exchange

Sponsored Content

MK Cell Out-License & Lyramid SPA Update

3 Nov 2025 07:00

RNS Number : 8172F

Roquefort Therapeutics PLC

03 November 2025

3 November 2025

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

MK Cell Out-License & Lyramid SPA Update

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces it has entered into an agreement to out-license its MK Cell patents to Pleiades Pharma Ltd ("Pleiades") in return for up to US$25 million in milestone cash payments together and a royalty payment obligation (the "MK Cell Out-License").

Background

As announced on 8 September 2025, the Company is proposing to acquire from A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers (the "Proposed Transaction"), retain the STAT-6 program and has ceased discussions around the sale of its wholly owned subsidiary Oncogeni Ltd. Further details on the progress of the Proposed Transaction will be announced in due course.

Following the announcement of the Proposed Transaction, the Company initiated discussions with Pleiades regarding the grant of an exclusive worldwide license for its MK Cell program, which has resulted in the signing of the MK Cell Out-License.

MK Cell Out-License

To accommodate the Group Restructuring (refer below) that was signalled in August 2025, the parties to the MK Cell Out-License are Roquefort Therapeutics' wholly owned subsidiary Midkine Investments Ltd ("Midkine Investments") and Pleiades. The consideration payable by Pleiades for the MK Cell Out-License is a combination of milestone cash payments and a royalty payment obligation of 1.5% perpetuity royalty on all global net sales of products derived from the licensed technology.

The total milestone cash payments of up to US$25 million is payable by Pleiades as follows:

a) US$500,000 upon Pleiades securing a minimum fundraising